BofA raised the firm’s price target on Humana (HUM) to $300 from $280 and keeps a Neutral rating on the shares. Managed Care payment year 2027 stars results were largely in line with expectations as a number of MCOs preannounced their ratings early, though Centene (CNC) and Elevance (ELV) “showed nice improvement in their stars, albeit off of depressed bases,” the analyst tells investors. The firm cites increased visibility for Humana to shift mix into 4 star plans after broker checks for its increased target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $345 from $300 at Mizuho
- Humana price target raised to $347 from $344 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Positive Outlook for Humana: Buy Rating Supported by Strategic Initiatives and Growth Projections
- Humana updates outside of star ratings positive, says Mizuho